Adjuvant EGFR TKIs May Enhance DFS in NSCLC

Share this content:
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment may be beneficial for non-small cell lung cancer (NSCLC).
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment may be beneficial for non-small cell lung cancer (NSCLC).

Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment may enhance disease-free survival and reduce the risk for developing distant metastasis in patients with EGFR mutation-positive non-small cell lung cancer who are undergoing complete resection, a study published in the journal Chest has shown.1

Because the role of EGFR TKIs in the adjuvant treatment of NSCLC has not been well defined, researchers sought to conduct a meta-analysis to determine whether treatment with these agents could improve the outcomes of patients undergoing complete resection for their disease.

For the study, researchers analyzed 5 studies that included a total of 1960 patients in order to assess the effect on disease-free survival, overall survival, and disease relapse.

Results showed that adjuvant EGFR TKI treatment was associated with a significant benefit on disease-free survival (HR, 0.86; 95% CI, 0.74 - 1.00). In particular, researchers found that in studies with a median treatment duration of more than 18 months, the survival benefit with adjuvant EGFR TKIs was superior.

EGFR mutation-positive patients specifically benefitted even more with adjuvant EGFR TKI therapy, with an absolute disease-free survival benefit of 9.5% at 3 years and a reduced risk of distant metastasis (OR, 0.71; 95% CI, 0.56 - 0.92). There was also a marginally statistically significant benefit on overall survival with this treatment approach (HR, 0.72; 95% CI, 0.49 - 1.06).

In terms of safety, grade 3 or higher adverse events occurred in 42.3% (95% CI, 39.1 - 45.6) of patients.

Reference

  1. Huang Q, Li J, Sun Y, et al. Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small-cell lung cancer by a meta-analysis [published online ahead of print December 2015]. Chest. doi: 10.1016/j.chest.2015.12.017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs